menu
    • menu
    [{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"BioLineRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gloria Biosciences","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Gloria Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Gloria Biosciences \/ Gloria Biosciences"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Gloria Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Gloria Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Gloria Biosciences \/ Gloria Biosciences"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Gloria Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"GLS-010","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GLS-012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gloria Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GLS-012","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gloria Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gloria Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Gloria Biosciences

    Menu

    Gloria Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

                            Details : Motixafortide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : Motixafortide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide,G-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : BioLineRx

                            Deal Size : $279.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures

                            Details : Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.

                            Product Name : Aphexda

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $29.6 million

                            October 31, 2023

                            Lead Product(s) : Motixafortide,G-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : BioLineRx

                            Deal Size : $279.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervi...

                            Details : YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 06, 2023

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLS-012

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

                            Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 07, 2023

                            Lead Product(s) : GLS-012

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLS-012

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

                            Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 18, 2023

                            Lead Product(s) : GLS-012

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Sun Yat-sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

                            Details : Zimberelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 13, 2023

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Sun Yat-sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent...

                            Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (...

                            Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hodgkin Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 26, 2022

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for Recurrent or Refractory ...

                            Details : Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 30, 2021

                            Lead Product(s) : Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Gloria Biosciences

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

                            Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 04, 2019

                            Lead Product(s) : GLS-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth